The article focuses on the black box warning of the U.S. Food and Drug Administration (FDA) on the decreasing use of atypical antipsychotics in patients with dementia. It notes that the approved and off-label uses of the drugs declined due to the increased risk of mortality among the ...
The 2005 US Food and Drug Administration (FDA) black-box warning about increased mortality being linked to atypical antipsychotic (AAP) use in elderly patients with dementia may have had unintended consequences. However, at this point, the findings are "hypothesis generating," and more research is...
CONCLUSION: The FDA advisory was associated with decreases in the use of atypical antipsychotics, especially among elderly patients with dementia.doi:10.1001/archinternmed.2009.456DorseyE. RayArch Intern MedArchives of Internal MedicineDorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC: ...
The directors of nursing answered questions concerning policies about and use of antipsychotic medications.Measurements/ResultsThe most commonly reported intervention to manage symptoms in residents with dementia since the black box warning was to lower doses of antipsychotics. Over half of facilities ...
In April 2005, the Food and Drug Administration (FDA) issued a black box warning (BBW) regarding the risks of using atypical antipsychotics (AAPs) for behavioral disorders in elderly patients with dementia. The objective of the present study was to investigate the impact of the BBW on the ...
Objectives There are conflicting reports as to whether two FDA "black box" warnings regarding risk of mortality related to use of antipsychotic medications to treat patients aged 65+ with dementia and a growing body of evidence of other serious adverse effects has resulted in decreased use. This ...